ClinicalTrials.gg

Program

adecatumumab

Also written as “MT-201”, “Adecatumumab” and “Adecatumumab and FOLFOX”.

Its studies are mostly in Inflammatory Bowel Diseases · Colorectal Neoplasms, led by 2 companies.

Furthest: phase 2, since Jul 15, 20254 company-led studies, 2 open or runningNext primary completion: Apr 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Mirador Therapeutics32 open or runningphase 2since Jul 15, 2025Jul 15, 2025Apr 30, 2027phase 2 · NCT07113522
Amgen10 open or runningphase 2since Mar 20, 2009Mar 20, 2009none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 20, 2009First study: phase 2 study in Colorectal NeoplasmsNew to AmgenAmgen · NCT00866944 · 35 enrolled · France, Germany
  2. Jul 15, 2025Mirador Therapeutics's first study: phase 2 study in Inflammatory Bowel DiseasesNew to Mirador TherapeuticsMirador Therapeutics · NCT07113522 · 140 planned · United States, Canada, Georgia and more
  3. Oct 17, 2025Phase 1 study in Healthy VolunteerMirador Therapeutics · NCT07219368 · 56 enrolled · United States
  4. Aug 17, 2026Phase 1 study in Healthy VolunteerMirador Therapeutics · NCT07776782 · 25 planned · United States

Ahead

  1. Nov 12, 2026Primary completion: phase 1 study in Healthy VolunteerMirador Therapeutics · NCT07776782
  2. Apr 30, 2027Primary completion: phase 2 study in Inflammatory Bowel DiseasesMirador Therapeutics · NCT07113522

TargetBeta

EPCAM →read by rule
“Epithelial cell adhesion molecule inhibitor”ChEMBL 37, by rule

Other programs on EPCAM

ProgramCompanyFurthest phaseStudies
Anti-EpCAM/Anti-4-1BB Bispecific Antibody BNT314ruleBioNTechphase 22
LTZ-232ruleltz-therapeutics-incphase 11

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07776782Healthy Volunteer · United States1RecruitingMirador TherapeuticsNov 12, 202625
NCT07219368Healthy Volunteer · United States1CompletedMirador TherapeuticsOct 20, 202656
NCT07113522Inflammatory Bowel Diseases · United States, Canada, Georgia and more2RecruitingMirador TherapeuticsApr 30, 2027140
NCT00866944Colorectal Neoplasms · France, Germany2CompletedAmgenJul 201135

How it is read

Names in the registry

  • “MT-201”, 3 entries
  • “Adecatumumab”, 1 entry
  • “Adecatumumab and FOLFOX”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.